AMPH

Across TCGA pan-cancer cohorts, AMPH Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated AMPH data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AMPH Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AMPH expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.

LUAD, UCEC, and SCLC are the cancer types where AMPH Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.154	0.674	<.001	36	view →
UCEC	DFS	Median	II,III,IV	0.933	0.430	.009	22	view →
SCLC	OS	Median	IV	0.959	0.274	.010	19	view →
KIRC	OS	Median	All	0.170	0.811	.001	12	view →
BLCA	OS	Median	All	0.173	0.620	<.001	12	view →
ESCA	OS	Median	All	0.198	0.872	.003	12	view →
GBM	OS	Median	All	0.140	0.415	.013	6	view →
READ	OS	Median	II,III,IV	0.187	0.653	.030	6	view →
LUSC	DFS	Median	All	0.709	0.355	.010	6	view →
LIHC	DFS	Median	All	0.204	0.557	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

AMPH–LUAD (OS)

Open the LUAD breakdown →